NCT04194775进行中（未招募）3 期
A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of Nofazinlimab (CS1003) in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Advanced Hepatocellular Carcinoma (HCC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 534
- 试验地点
- 126
- 主要终点
- Overall survival (OS)
研究概览
简要总结
This is a multi-center, double-blind, randomized, phase III study to investigate the efficacy and safety of Nofazinlimab (CS1003) in combination with lenvatinib and placebo in combination with lenvatinib in the treatment of subjects with no prior systemic treatment and with unresectable advanced hepatocellular carcinoma (HCC). Subjects cannot be eligible for locoregional therapy. In this study, Nofazinlimab (CS1003) (or placebo) and lenvatinib are both considered as the study treatment while Nofazinlimab (CS1003) (or placebo) is the investigational product and lenvatinib is selected as the basic treatment for HCC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years on the day of signing informed consent-(For Taiwan, the lower limit of age is 20 years).
- •Subjects with unresectable advanced HCC, that is not eligible for surgery and/or locoregional therapy (Stage B or C based on Barcelona Clinic Liver Cancer [BCLC] staging system, and meets either one of the following criteria: 1) histologically or cytologically confirmed diagnosis of HCC, 2) clinically confirmed diagnosis of HCC according to American Association for the Study of Liver Diseases (AASLD) criteria. Patients without cirrhosis require histological confirmation of diagnosis.
- •With at least one measurable lesion can be assessed
- •Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or
- •Life expectancy ≥ 3 months.
- •Child-Pugh A
- •No prior systemic treatment for advanced HCC
- •Subjects with hepatitis B virus (HBV) infection, are willing to continue receiving antiviral treatment while on study.
- •Subjects have adequate organ and marrow function. Female subjects with childbearing potential must have negative serum pregnancy test result at screening. Female subjects with childbearing potential, and male subjects and their female partners with childbearing potential must agree to use an contraceptive method(s) from the day of signing informed consent form (ICF), during the study and till at least 6 months after the last dose of study treatment.
排除标准
- •Fibrolamellar-HCC, sarcomatoid, cholangiocellular carcinoma or mixed cholangiocarcinoma and HCC.
- •A prior bleeding event due to esophageal within 6 months or other gastrointestinal bleeding events within 28 days prior to screening.
- •Malabsorption syndrome or inability to take oral medication due to other causes.
- •HBV and HCV co-infection.
- •Investigator evaluates to increase the drug related risk caused by enrolling subjects in trial and taking study drug, or any serious or uncontrolled systematic disease that confound the drug absorption or the study outcome, e,g diabetes mellitus, hypertension, rheumatoid arthritis, major cardiovascular disease and so on.
- •Surgery or locoregional therapy for palliative purpose within 4 weeks prior to study treatment.
- •History of other malignancy(ies) in the past 5 years, except for malignant disease treated with curative intent and without active disease.
- •Known history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).
- •Current or prior use of systemic corticosteroid (> 10 mg/day prednisone or equivalent) or other immunosuppressive medication within 14 days prior to the first dose of study treatment.
- •History of bone marrow transplantation or organ transplantation.
- •History of anaphylaxis or hypersensitivity to any ingredient of the investigational product.
- •Any contraindication of lenvatinib.
- •Known history of drugs abuse that would interfere with cooperation with the requirements of the trial.
- •Pregnant or lactating female subjects.
- •History of psychiatric disease that would interfere with cooperation with the requirements of the trial; lack of or with restricted physical capability.
- •QTc interval > 470 msec (as calculated with Fridericia's formula) at screening electrocardiogram (ECG);
- •Any condition that would in the investigator's judgment, prevent the subject from participating in this study.
研究组 & 干预措施
Nofazinlimab (CS1003)
Experimental
干预措施: Nofazinlimab (CS1003)+Lenvatinib (Drug)
Nofazinlimab (CS1003) placebo
Placebo Comparator
干预措施: Nofazinlimab (CS1003) Placebo+Lenvatinib (Drug)
结局指标
主要结局
Overall survival (OS)
时间窗: Expected to be 5.5 years after the first patient is enrollment.
Overall Survival (OS)
时间窗: From enrollment to end of follow-up, a median of 42.5 months
OS was defined as the time interval between the date of randomization to the date of death from any cause.
次要结局
- Objective response rate (ORR) evaluated by investigators based on RECIST v1.1(Expected to be 5.5 years after the first patient is enrollment.)
- Duration of response (DoR) evaluated by blinded independent central review committee(BICR) based on Response Evaluation Criteria in Solid Tumors(RECIST) v1.1(Expected to be 5.5 years after the first patient is enrollment.)
- Duration of response (DoR) evaluated by investigators based on Response Evaluation Criteria in Solid Tumors(RECIST) v1.1(Expected to be 5.5 years after the first patient is enrollment.)
- Disease control rate (DCR) evaluated by blinded independent central review committee(BICR) based on Response Evaluation Criteria in Solid Tumors(RECIST) v1.1(Expected to be 5.5 years after the first patient is enrollment.)
- Disease control rate (DCR) evaluated by investigators based on Response Evaluation Criteria in Solid Tumors(RECIST) v1.1(Expected to be 5.5 years after the first patient is enrollment.)
- Percentage of Participants with Adverse Events(Expected to be 5.5 years after the first patient is enrollment.)
- Peak and trough serum concentrations of CS1003(Expected to be 5.5 years after the first patient is enrollment.)
- Number and percentage of subjects who develop anti-CS1003 antibody (ADA)(Expected to be 5.5 years after the first patient is enrollment.)
- Objective response rate (ORR) assessed by blinded independent central review committee(BICR)(Expected to be 5.5 years after the first patient is enrollment.)
- Progression-free survival(PFS) evaluated by investigator based on RECIST v1.1(Expected to be 5.5 years after the first patient is enrollment.)
- Progression-free survival(PFS) assessed by blinded independent central review committee(BICR) based on Response Evaluation Criteria in Solid Tumors(RECIST) v1.1(Expected to be 5.5 years after the first patient is enrollment.)
- Time to deterioration (TTD), defined as the time from randomization to the first deterioration of European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) scale(Expected to be 5.5 years after the first patient is enrollment.)
- Disease Control Rate (DCR) Evaluated by Investigators Based on Response Evaluation Criteria in Solid Tumors(RECIST) v1.1(From enrollment to end of follow-up, a median of 42.5 months)
- Objective Response Rate (ORR) Assessed by Blinded Independent Central Review Committee(BICR)(From enrollment to end of follow-up, a median of 42.5 months)
- Progression-free Survival(PFS) Assessed by Blinded Independent Central Review Committee(BICR) Based on Response Evaluation Criteria in Solid Tumors(RECIST) v1.1(From enrollment to end of follow-up, a median of 42.5 months)
- Progression-free Survival(PFS) Evaluated by Investigator Based on RECIST v1.1(From enrollment to end of follow-up, a median of 42.5 months)
- Objective Response Rate (ORR) Evaluated by Investigators Based on RECIST v1.1(From enrollment to end of follow-up, a median of 42.5 months)
- Duration of Response (DoR) Evaluated by Blinded Independent Central Review Committee(BICR) Based on Response Evaluation Criteria in Solid Tumors(RECIST) v1.1(From enrollment to end of follow-up, a median of 42.5 months)
- Duration of Response (DoR) Evaluated by Investigators Based on Response Evaluation Criteria in Solid Tumors(RECIST) v1.1(From enrollment to end of follow-up, a median of 42.5 months)
- Disease Control Rate (DCR) Evaluated by Blinded Independent Central Review Committee(BICR) Based on Response Evaluation Criteria in Solid Tumors(RECIST) v1.1(From enrollment to end of follow-up, a median of 42.5 months)
- Percentage of Participants With Adverse Events(From enrollment to end of follow-up, a median of 42.5 months)
- Peak and Trough Serum Concentrations of CS1003(Peak: assessed post-dose (within 30 minutes after the end of infusion) on Cycle 4 Day 1; Trough: assessed pre-dose (within 60 minutes prior to infusion) on Cycle 4 Day 1 (cycle length = 21 days).)
- Number and Percentage of Subjects Who Develop Anti-CS1003 Antibody (ADA)(From enrollment to end of follow-up, a median of 42.5 months)
- Time to Deterioration (TTD), Defined as the Time From Randomization to the First Deterioration of European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Scale(From enrollment to end of follow-up, a median of 42.5 months)
研究者
研究点 (126)
Loading locations...
相似试验
已完成
3 期
A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung CancerNon Small Cell Lung CancerNCT03789604CStone Pharmaceuticals479
进行中（未招募）
3 期
A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal CancerGastric or Gastroesophageal Junction CancerNCT04950322Suzhou Suncadia Biopharmaceuticals Co., Ltd.737
招募中
2 期
A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)Metastatic Colorectal CancerNCT04547166Shanghai Henlius Biotech568
招募中
3 期
Efficacy and Safety of AJU-C52 in Essential Hypertension PatientsEssential HypertensionNCT06416865AJU Pharm Co., Ltd.190
已完成
3 期
A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction AdenocarcinomaGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaNCT03802591CStone Pharmaceuticals479